Litigation Details for Acrotech Biopharma, LLC v. Fresenius Kabi USA, LLC (D. Del. 2018)
✉ Email this page to a colleague
Acrotech Biopharma, LLC v. Fresenius Kabi USA, LLC (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-10-03 |
| Court | District Court, D. Delaware | Date Terminated | 2020-12-02 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | Sherry R. Fallon |
| Parties | FRESENIUS KABI ONCOLOGY LTD. | ||
| Patents | 6,888,027; 8,835,501 | ||
| Attorneys | Helen H. Ji | ||
| Firms | Farnan LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Acrotech Biopharma, LLC v. Fresenius Kabi USA, LLC
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Acrotech Biopharma, LLC v. Fresenius Kabi USA, LLC (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-10-03 | 1 | U.S. Patent Nos. 6,888,027 (the “’027 patent”) and U.S. Patent No. 8,835,501 (the “’501 patent”) under…the ’027 patent and the ’501 patent, or any later expiration of exclusivity for the ’027 patent and the… THE PATENTS-IN-SUIT 28. On May 3, 2005, the ’027 patent, titled “Carbamic Acid…United States Patent and Trademark Office (“PTO”). A true and correct copy of the ’027 patent is attached…of the ’501 patent is attached as Exhibit B. 31. The claims of the ’501 patent are directed | External link to document | |
| 2020-08-25 | 103 | Notice of Service | Williams III, Ph.D. Regarding Validity of U.S. Patent No. 8,835,501; (2) Rebuttal Expert Report of Robert R.…2018 2 December 2020 1:18-cv-01533 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-09-08 | 106 | Redacted Document | seek to enforce Patent Nos. 6,888,027 (“the ’027 patent) and 8,825,501 (“the ’501 patent”). Plaintiffs… the ’027 patent, Plaintiffs’ experts asserted only 2 out of the 63 claims in that patent — claims 37…asserted—specifically, claims 53 and 57 of the ’027 patent. When asked at a meet and confer whether…infringement for claims 53 and 57 of the ’027 patent, even though their opening infringement reports…surprise. That is because, under Plaintiffs’ view, a patent owner can game the system by issuing opening expert | External link to document |
| 2020-09-28 | 115 | Notice of Service | Besterman, Ph.D Regarding Invalidity of U.S. Patent No. 6,888,027 and (ii) Reply Expert Report of Dr. Alexander…2018 2 December 2020 1:18-cv-01533 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-12-02 | 126 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,888,027 ;US 8,835,501. (Attachments…2018 2 December 2020 1:18-cv-01533 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2018-10-03 | 4 | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) U.S. 6,888,027 ;U.S. 8,835,501.…2018 2 December 2020 1:18-cv-01533 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2020-07-13 | 99 | Notice of Service | Besterman, Ph. D Regarding Invalidity of U.S. Patent No. 6,888,027 filed by Fresenius Kabi USA, LLC.(Farnan…2018 2 December 2020 1:18-cv-01533 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
